Please login to the form below

Not currently logged in
Email:
Password:

EU approval for Gilenya

Novartis' oral multiple sclerosis drug Gilenya has been approved as the first treatment of its kind for use in the European Union

Novartis' oral multiple sclerosis (MS) drug Gilenya (fingolimod) has been approved as the first treatment of its kind for use in the European Union (EU).

The drug is approved for use in patients with highly active relapsing-remitting multiple sclerosis (RRMS) who have already undergone treatment with beta interferon, or have a rapidly evolving severe form of the condition.

The announcement follows the US Food and Drug Administration's (FDA) decision to approve Gilenya for use in the US after trials showed it reduced the frequency of relapse and reduced the risk of disease progression.

It has also been approved in other regions including Switzerland and Australia.

The EU approval was preceded by a positive opinion of Gilenya from the Committee for Medicinal Products for Human Use (CHMP), an expert committee of the European Medicines Agency (EMA).

Gilenya has fared better than other oral MS treatments, including Merck Serono's cladribine. Despite being approved in Russia under the trade name Movectro, it was recently denied US approval and was given a negative opinion by CHMP.

21st March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....